Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis

Li Dong; Luo TianYang; Ran YaWei

doi:10.3969/j.issn.1001-5256.2019.10.017

Volume 35 Issue 10

Oct. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(10): 2214-2219

PDF( 1323 KB)

Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.10.017

Imaging Center,The First people's Hospital of Baiyin

Received Date: 2019-05-27
Published Date: 2019-10-20

Abstract

Abstract

Objective To systematically evaluate the value of contrast-enhanced computed tomography(CECT) and contrast-enhanced magnetic resonance imaging(CEMRI) in the diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization(TACE)in hepatocellular carcinoma(HCC). Methods Pub Med,Embase,Cochrane Library,Web of Science,CNKI,and Wanfang Data were searched for studies on CECT and/or CEMRI in the diagnosis of residual or recurrent lesion after TACE published up to April 2019. After two reviewers independently performed literature screening,data extraction,and assessment of the risk of bias using the QUADAS-2 tool,Stata 12. 0 and Rev Man 5. 3 were used to analyze pooled sensitivity,specificity,and area under the receiver operator characteristic curve(AUC). Results A total of 13 studies on CECT and 13 studies on CEMRI in the diagnosis of residual or recurrent HCC lesion after TACE were included,with 934 lesions from 748 patients and 847 lesions from 557 patients,respectively. High heterogeneity was observed in the 13 studies on CECT in the diagnosis of residual or recurrent HCC lesion after TACE(P = 0. 001,Q = 12. 56,I2= 84. 08%),while no significant heterogeneity was observed in the 13 studies on CEMRI(P = 0. 473,Q = 0. 11,I2= 0). In the diagnosis of residual or recurrent HCC lesion after TACE,CECT had a sensitivity of 72%(95% confidence interval [CI]: 66%-78%),a specificity of 99%(95% CI: 93%-100%),and an AUC of 0. 87(95% CI: 0. 83-0. 89),and CEMRI had a sensitivity of 88%(95% CI: 82%-93%),a specificity of 96%(95% CI: 91%-98%),and an AUC of 0. 98(95% CI: 0. 96-0. 99). CECT had a significantly lower sensitivity than CEMRI in the diagnosis of residual or recurrent HCC lesion after TACE(Z = 2. 12,P = 0. 03). Conclusion In comparison with CECT,CEMRI has an extremely higher diagnostic efficiency in the diagnosis of residual or recurrent HCC lesion after TACE and is thus an effective method for diagnosis.
- carcinoma,hepatocellular,
- tomography,X-Ray computed,
- magnetic resonance imaging,
- Meta-analysis as topic

FullText(HTML)

References(34)

References

[1] Chinese College of Interventionalists. Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. J Intervent Radiol,2018,27(12):1117-1126.(in Chinese)中国医师协会介入医师分会．中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]．介入放射学杂志，2018,27(12):1117-1126.

[2] PAGE AJ,COSGROVE DC,PHILOSCOPHE,et al. Hepatocellular carcinoma:Diagnosis,management,and prognosis[J]. Surg Oncol Clin N Am,2014,23(2):289-311.

[3] WHITING PF,RUTIES AW,WESTWOOD ME,et al. QUADAS-2:A revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med,2011,158(8):529-536.

[4] CHO YZ,PARK SY,CHOI EH,et al. The usefulness of contrastenhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization:Pilot study[J]. Clin Mol Hepatol,2015,21(2):165-174.

[5] CHOI SJ,KIM J,SEO J,et al. Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization[J]. Euro Radiol,2016,26(1):225-234.

[6] JANG KM,CHOI D,LIM HK,et al. Depiction of viable tumor in hepatocellular carcinoma treated with transarterial chemoembolization:Multiphasic helical CT with review of the previous serial CT images[J]. Korean J Radiol,2005,6(3):153-160.

[7] KIM HJ,KIM TK,KIM PN,et al. Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization:Comparison of enhanced sonography and 3-phase computed tomography[J].J Ultrasound Med,2006,25(4):477-486.

[8] LIU M,LIN MX,LU MD,et al. Comparison of enhanced ultrasound and computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST[J]. Euro Radiol,2015,25(8):2502-2511.

[9] PAUL SB,DHAMIJA E,GAMANAGATTI SR,et al. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma:Comparison of contrast-enhanced ultrasound with MSCT[J]. Diagn Interv Imaging,2017,98(3):253-260.

[10] SALVAGGION G,CAMPISI A,GRECO V,et al. Evaluation of posttreatment response of hepatocellular carcinoma:Comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT[J]. Abdom Imaging,2010,35(4):447-453.

[11] SHANG JB,LIU FY,LI YH,et al. A comparative study of 18F-FDG PET,CT and angiography in the follow up of primary liver carcinoma after transarterial chemoembolization[J]. J Chin Clin Med Imaging,2004,15(9):509-512,529.(in Chinese)商健彪，刘方颖，李彦豪，等．(18)F-FDG PET、CT和血管造影在原发性肝癌TACE后随访的对比研究[J]．中国临床医学影像杂志，2004,15(9):509-512,529.

[12] SI XW,ZHOU HL,CHEN HP,et al. Evaluation of the effect of MRI and CT in primary hepatocellular carcinoma after TACE[J].Med J West China,2017,29(8):1150-1153.(in Chinese)斯兴无，周红俐，陈华平，等．MRI与CT对原发性肝癌TACE术后的疗效评估[J]．西部医学，2017,29(8):1150-1153.

[13] TAKIZAWA K,NUMATA K,MORIMOTO M,et al. Use of contrast-enhanced ultrasonography with a contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable HCC[J]. Euro J Radiol,2013,82(9):1471-1480.

[14] WANG X,LI D,HE F,et al. Contrastive analysis of contrastenhanced ultrasound and enhanced CT in evaluating the efficacy of TACE in the treatment of primary liver cancer[J]. Hebei Med,2018,24(7):1113-1116.(in Chinese)王曦，李东，何芬，等．超声造影与增强CT评估TACE治疗原发性肝癌疗效的价值对比[J]．河北医学，2018,24(7):1113-1116.

[15] XIANG K,ZHAO HL,ZHENG CY,et al. Comparison of assessment value of 16-slice spiral CT and MRI for lesions of primary hepatic carcinoma after TACE surgery[J]. Pract J Cancer,2014,29(10):1315-1317,1321.(in Chinese)项昆，赵鹤亮，郑昌英，等．16排螺旋CT和MRI对原发性肝癌TACE术后病灶的疗效判断价值对比[J]．实用癌症杂志，2014,29(10):1315-1317,1321.

[16] YANG ML,YANG ZY,XIE CM. Comparative study on digital substraction angiography and CT diagnosis for the residual and new lesions of PHC after transcatheter arterial chemoembolization[J]. Cancer Res Clin,2014,26(3):145-147,152.(in Chinese)杨敏玲，杨志勇，谢春明．原发性肝癌经导管肝动脉化疗栓塞术后肿瘤残留及新发病灶的CT和数字减影血管造影诊断对比研究[J]．肿瘤研究与临床，2014,26(3):145-147,152.

[17] BOLOG N,PFAMMATTER T,MULLHAUPT B,et al. Doublecontrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization[J]. Abdom Imaging,2008,33(3):313-323.

[18] CEN YM,LIANG JW,TANG XY,et al. Comparison of CT and MR scan for primary hepatic carcinoma after TACE[J]. J Hepatobiliary Surg,2016,24(5):347-350.(in Chinese)岑裕铭，梁甲伟，唐小勇，等．原发性肝癌TACE术后活性灶的CT和MR对比较[J]．肝胆外科杂志，2016,24(5):347-350.

[19] FENG DP,LI NA,WANG XC,et al. Value of MRI in assessing residual tumor of hepatocellular carcinoma in patients with accumulation deposition of lipiodol after TACE[J/CD]. Chin J Inter Rad:Electronic Edition,2014,2(3):6-19.(in Chinese)冯对平，李丽娜，王效春，等．肝癌碘油栓塞后沉积良好患者的MRI随访临床研究[J/CD]．中华介入放射学电子杂志，2014,2(3):6-19.

[20] GOSHIMA S,KANEMATSU M,KONDO H,et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization:Is diffusion-weighted MRI reliable as an indicator?[J]. J Magn Reson Imaging,2008,27(4):834-839.

[21] GUO CG,ZHANG JF,XU SL,et al. Diffusion weighted imaging combined with dynamic contrast enhanced magnetic resonance imaging in monitoring therapeutic efficacy for hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. J Zhejiang Uuiversity:Medical Science,2014,43(1):77-82,88.(in Chinese)过川根，张景峰，许顺良．磁共振弥散加权成像联合动态增强在肝癌患者TACE术后病灶残留及复发监测中的应用价值[J]．浙江大学学报:医学版，2014,43(1):77-82,88.

[22] KALB B,CHAMSUDDIN A,NAZAAL L,et al. Chemoembolization follow-up of hepatocellular carcinoma with MR imaging:Usefulness of evaluating enhancement features on onemonth posttherapy MR imaging for predicting residual disease[J]. J Vasc Interv Radiol,2010,21(9):1396-1404.

[23] LIU R,WANG JH,ZHOU KR,et al. A comparative study of CT and MRI in the follow-up of hepatocellular carcinoma after transcatheter arterial chemoembolization with lipiodol[J]. J Practical Radiology,2003,19(10):902-905.(in Chinese)刘嵘，王建华，周康荣，等．原发性肝癌TACE后CT和MRI随访的对照研究[J]．实用放射学杂志，2003,19(10):902-905.

[24] PAN L,ZHENG DW. Evaluation of MSCT and MRI on the postoperatively curative effect of TACE for patient with PHC[J].China Med Equipment,2018,15(8):45-48.(in Chinese)潘利，郑大伟．多层螺旋CT与磁共振成像对原发性肝癌经肝动脉化疗栓塞术后疗效评价[J]．中国医学装备，2018,15(8):45-48.

[25] WEI J,DUAN Q,XUE YJ,et al. Dynamic contrast-enhanced VIBE sequence at 3. 0T MR:Assessment of therapeutic effect of transcatheter arterial chemoembolization for hepatocellucer carcinoma[J]. Chin J Interv Imaging,2008,5(2):115-118.(in Chinese)威晋，段青，薛蕴菁，等．3. 0T VIBE序列动态增强磁共振检查在评估经导管肝动脉化疗栓塞术治疗肝细胞癌疗效中的价值[J]．中国介入影像与治疗学，2008,5(2):115-118.

[26] YANG YW,WANG ZT,WANG Y,et al. MR diffusion weighted imaging in the prognosis evaluation of liver cancer after treatment of transcatheter arterial chemoembolization[J]. J Pract Radiol,2018,34(4):600-602,605.(in Chinese)杨耀文，王志涛，王颖．MR DWI在肝癌TACE术后评估中的应用研究[J]．实用放射学杂志，2018,34(4):600-602,605.

[27] YANG ZC. Clinical analysis of CT and MRI in evaluating tumor residual and lesion stability after primary hepatocellular carcinoma with TACE[J]. Inter Med Health Guid News,2014,20(4):512-514.(in Chinese)杨忠诚．CT和MRI评价原发性肝癌TACE治疗后肿瘤残存和病灶稳定性的临床分析[J]．国际医药卫生导报，2014,20(4):512-514.

[28] YIM JH,KIM YK,Min JH,et al. Diagnosis of recurrent HCC:Intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI[J]. Abdom Radiol(NY),2019,44(7):2366-2376.

[29] ZHAO LF,WANG CS,ZHANG YF,et al. Preliminary study of CT perfusion and MRI of hepatocelluar carcinoma after fist transcatheter chemoem-bolization with lipiodol[J]. Chin J Misdiag,2009,9(16):3783-3785.(in Chinese)赵立峰，王昌生，张妍芬，等．原发性肝癌首次TACE术后CT灌注与MRI的研究初探[J]．中国误诊学杂志，2009,9(16):3783-3785.

[30] WALLACE MC,PREEN D,JEFFREY GP,et al. The evolving epidemiology of hepatocellular carcinoma:A global perspective[J]. Expert Rev Gastroenterol Hepatol,2015,9(6):765-779.

[31] BRAY F,FERALY J,SOERJOMATARAM,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[32] KIM J,CHOI SJ,LEE SH,et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization:Comparison of models using radiomics[J]. AJR Am J Roentgenol,2018,211(5):1026-1034.

[33] LIU HF,XU YS,ZHANG Y,et al. Value of magnetic resonance morphological imaging in the diagnosis and differentiation of post-hepatitis B cirrhosis[J]. J Clin Hepatol,2018,34(12):2587-2591.(in Chinese)刘海峰，许永生，张跃，等．MR形态学成像在乙型肝炎肝硬化诊断及分期中的应用价值[J]．临床肝胆病杂志，2018,34(12):2587-2591.

[34] LEITAO HS,DOBLAS S,GARTEISER P,et al. Hepatic fibrosis,inflammation,and steatosis:Influence on the MR Viscoelastic and diffusion parameters in patients with chronic liver disease[J]. Radiology,2017,283(1):98-107.

Relative Articles

[1]	Lu HUANG, Lijian LU. Value of MRI biliary score and liver/muscle ratio in evaluating the pathological grade of liver fibrosis[J]. Journal of Clinical Hepatology, 2024, 40(4): 720-725. doi: 10.12449/JCH240413
[2]	Zhiran YANG, Linheng WANG, Yuan LI, Fusheng LIU, Yu WANG, Jianfang WANG, Runhua CHEN. Diagnostic value of transient elastography in the staging of hepatic fibrosis in patients with autoimmune liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(1): 97-103. doi: 10.3969/j.issn.1001-5256.2022.01.015
[3]	Weiming YU, Wenqian HONG, Binglun SUN, Jingzhao HAN, Hongfang TUO. Value of albumin-bilirubin grade in predicting liver function changes and prognosis of hepatocellular carcinoma patients undergoing transarterial chemoembolization: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(11): 2575-2583. doi: 10.3969/j.issn.1001-5256.2021.11.018
[4]	Ying LIU, Benjian GAO, Xiaoli YANG, Cheng FANG, Song SU, Bo LI. Effect of hemihepatic vascular exclusion versus total hepatic vascular exclusion in hepatectomy for primary liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(1): 73-78. doi: 10.3969/j.issn.1001-5256.2021.01.015
[5]	Minjun LI, Zhujian DENG, Haotian LIU, Yuxian TENG, Rongrui HUO, Xiumei LIANG, Bangde XIANG, Lequn LI, Jianhong ZHONG. Clinical effect of re-hepatic resection versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma in Asia: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1103-1109. doi: 10.3969/j.issn.1001-5256.2021.05.025
[6]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[7]	Yu PeiHe, Su Song, Chen Shi, Wang JinCheng, Chen XinPei, Luo De. Clinical effect of pancreaticoduodenectomy with total mesopancreas excision versus traditional pancreaticoduodenectomy in treatment of pancreatic head carcinoma and periampullary cancer:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1811-1815. doi: 10.3969/j.issn.1001-5256.2020.08.026
[8]	Zhang Bin, Luo De, Peng FangYi, Fang Cheng, Gan Yu, He Kai, Li Bo, Xia XianMing, Su Song. Clinical effect of robot-assisted laparoscopic hepatectomy versus open hepatectomy in treatment of liver diseases:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1778-1782. doi: 10.3969/j.issn.1001-5256.2020.08.020
[9]	Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
[10]	Qian Le, Ying Li. Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2015-2020. doi: 10.3969/j.issn.1001-5256.2020.09.021
[11]	Tang JinQuan, He Pan, Su Song, Luo Bin, Fang Cheng, Li Bo, Xia XianMing, Li YuWei. Short-and long-term effects of radiofrequency ablation versus minimally invasive hepatectomy in treatment of small hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 358-362. doi: 10.3969/j.issn.1001-5256.2020.02.025
[12]	Fan MengJie, Zeng Zheng. Influence of dual positivity of HBsAg and anti-HBs on the development of hepatocellular carcinoma in patients with chronic hepatitis B: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1723-1727. doi: 10.3969/j.issn.1001-5256.2019.08.015
[13]	Pan Qi, Luo ChunHai, Ma WanLing, Qu YuanFei, Wang JianRu, Chen Lin. Specific magnetic resonance imaging of vascular endothelial growth factor-C targeted molecular probe and its clinical significance in a rat model of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(7): 1492-1496. doi: 10.3969/j.issn.1001-5256.2018.07.025
[14]	Chen QiPing, Lin Su, Shi ZhenShan, Zhu YueYong, Li YouBing. A cost-effectiveness analysis of Gd-EOB-DTPA contrast-enhanced magnetic resonance imaging versus ultrasound in hepatocellular carcinoma screening[J]. Journal of Clinical Hepatology, 2018, 34(9): 1917-1920. doi: 10.3969/j.issn.1001-5256.2018.09.018
[15]	Yan FuHua. Research advances in computed tomography and magnetic resonance imaging findings of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(6): 1079-1082. doi: 10.3969/j.issn.1001-5256.2016.06.011
[16]	Wu Jie, Jing ZongLin. Research advances in MRI features and diagnosis of hepatocellular adenomas[J]. Journal of Clinical Hepatology, 2016, 32(10): 2012-2015. doi: 10.3969/j.issn.1001-5256.2016.10.045
[17]	Luo YongHeng, Xiao EnHua. Role of functional magnetic resonance imaging in evaluating the therapeutic effect of transcatheter arterial chemoembolization in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(12): 2277-2281. doi: 10.3969/j.issn.1001-5256.2016.12.010
[18]	Wang LiLi, Lei JunQiang, Guo JiGang, Yin Liang, Zhai YaNan, Li JinKui, Chen Hong, Guo ShunLin. Value of Gd-EOB-DTPA-enhanced MRI in assessing liver function[J]. Journal of Clinical Hepatology, 2015, 31(5): 749-753. doi: 10.3969/j.issn.1001-5256.2015.05.028
[19]	Gu Han, Li Cheng. Research progress in magnetic nanoparticles for magnetic resonance imaging and targeted therapy of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(10): 740-743. doi: 10.3969/j.issn.1001-5256.2013.10.005
[20]	Zhao GuoKu, Chen Kai, Zhou HongWei. MRI diagnostic value of liver adenoma[J]. Journal of Clinical Hepatology, 2004, 20(5): 291-292+321.

Supplements(0)

Cited By

Cited by

Periodical cited type(10)

1.	刘听潮，张示杰，杨婧，彭心宇，马儒林，郭恒，张向辉，何佳，郭淑霞. 新疆维吾尔族农村居民肝纤维化评分与心血管疾病发病关系前瞻性队列研究. 中国公共卫生. 2025(02): 154-160 .
2.	卢晶，朴红心，金雪梅，崔京淑，金仁顺. 慢性乙型肝炎肝纤维化抗病毒治疗后生活质量与AST/PLT比率、肝硬度值、病理组织学的相关性分析. 临床肝胆病杂志. 2021(04): 813-816 . 本站查看
3.	刘红虹，福军亮，洪智贤，靳雪原，陈曦，王文苓，王冶，赵艳玲. 肝纤维化血清学无创检测研究进展. 传染病信息. 2021(04): 347-352 .
4.	魏鑫，徐懂，龙细雨，伍喜良，郭丽颖，贾建伟. 基于血清Fe和CA199预测模型对慢性乙型肝炎患者肝纤维化分期的临床研究. 中西医结合肝病杂志. 2021(10): 869-873 .
5.	郑少秋，王启之. 无创肝纤维化诊断研究现状与前景. 临床肝胆病杂志. 2019(01): 197-200 . 本站查看
6.	徐莉力，王佳冰，杨华睿，童明辉. 肝、脾二维实时剪切波弹性成像技术及血清纤维化模型对CHB肝脏纤维化程度的评估原理与应用. 武警医学. 2019(02): 169-173 .
7.	吴方雄，闫蓉，高保华，田秋梅，徐静远，鲁晓岚. RPR FIB-4 APRI及AAR对107例慢性乙型肝炎肝纤维化的诊断准确性比较. 中国实用内科杂志. 2019(03): 249-253 .
8.	张丽杰，张古城，申弘，胡萌，张均倡. 中西医结合治疗对乙肝肝硬化代偿期患者逆转情况的队列研究. 湖南师范大学学报(医学版). 2019(01): 34-38 .
9.	许峰铭，盛庆寿. 血清标志物与瞬时弹性成像技术评估肝纤维化的研究进展. 临床肝胆病杂志. 2018(03): 618-622 . 本站查看
10.	富慧文. 血府逐瘀汤治疗慢性乙型肝炎肝纤维化的效果研究. 名医. 2018(08): 9+14 .

Other cited types(14)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (676) PDF downloads(141)

Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.10.017